Generate:Biomedicines

From generative design to data-driven validation, protein engineering is moving fast. Join this session at GEN’s “The State of AI in Drug Discovery” for what’s next. Session: The Rise of AI in Protein Design Speakers: Surge Biswas, PhD (Nabla Bio); Tharindi Hapuarachchi, PhD (Generate:Biomedicines); Oliver Vince, PhD (Basecamp Research) When: Wednesday, October 29 • 3:00 PM–3:30 PM (EDT) What you’ll learn • How AI models are expanding the design space for novel proteins • Practical use cases from platform companies and emerging tools • Where the field is headed and what hurdles remain Summit runs 11:00 AM–3:40 PM (EDT). ✅ Registration is FREE 🔗 https://hubs.li/Q03NvF400 #AI #ProteinDesign #SyntheticBiology #Biotech #GENBiotech

How can we make the promise of #AI in cancer care real? At the Prostate Cancer Foundation’s “32nd Annual Scientific Retreat”— a cross-disciplinary forum where leaders in academia, biotech, and medicine explore breakthroughs in #CancerResearch — Alex Therien, Ph.D., our SVP and Head of Drug Design & Preclinical Development, will share how we are using #GenerativeAI to intentionally design medicines that address cancer’s complexity with greater precision, speed, and scale. Our efforts are focused on applying our platform to build new kinds of therapies — starting with immune cell engagers, engineered CAR-Ts, and our payload neutralizer designed to reduce toxicity from antibody-drug conjugates. Can’t make the talk? Watch how we’re approaching ADC toxicity: https://lnkd.in/ek8rD-Jj #Oncology | #ProgrammingBiology 

How do you build infrastructure that turns data into a strategic asset? Stephen Kottmann, our Head of Informatics, joined Brad Loncar on BiotechTV to walk through the systems behind our design, build, test, learn loop—describing how we generate millions of sequences, move them through automated workflows, and return high-quality data into our models. The goal, as Stephen put it, is to move from “a chance-oriented process to one that’s engineered, predictable, reliable, repeatable, and very fast.” Watch the conversation below. ⬇️ #ProgrammingBiology | #DesignedToScale

Tomorrow, our co-founder and CTO, Gevorg Grigoryan, Ph.D., will speak at the 10-year celebration of the Models, Inference & Algorithms (MIA) Initiative at the Broad Institute — a community built to connect biology, medicine, and #MachineLearning.     Alongside Alex Bloemendal of the Broad Institute of MIT and Harvard and MIA co-founder, Aleksandrina Goeva of University of Toronto, and Aviv Regev of Genentech, this panel will explore how mathematics, statistics, and computation continue to shape the future of biomedical science.    This is the kind of interdisciplinary thinking that shaped Gevorg’s path — and ultimately, the founding vision behind Generate. Learn more: https://lnkd.in/eFrVzWX8 #GenerativeBiology | #ProteinEngineering

A new article in Healio spotlights Phase 1 results for GB-0895, our #AI-engineered antibody that targets TSLP, a key driver of airway inflammation in #asthma. The piece highlights data showing six-month pharmacology following a single dose and perspectives from lead investigator Professor Dave Singh, MD, on how long-acting biologics could help reduce treatment burden for patients with severe asthma. External coverage like this illustrates how the ability to program biology is moving from scientific concept to clinical reality, helping define what’s next in respiratory care. Read the full article → https://lnkd.in/eSbJWAZF #ERS2025 | #GenerativeAI

Progress isn’t just about what’s ahead — it’s about honoring how you got there. Recently, #TeamGenerate came together for a 6.3-mile bike ride — a journey from our earliest offices at One Kendall Square to our current home at Boynton Yards. Along the way, original Generators (our OG:’s) shared stories that brought each location to life. Organized by members of our thriving Bike Committee, the ride was a moving reminder of how far we’ve come. History isn’t just a reminder of our past — it’s the momentum that drives us forward. Does this sound like a ride you want to be part of? Join us: https://lnkd.in/gKaKkEGJ #ThisisGenerate | #NowWeCan 

#AI isn’t just accelerating drug discovery – it’s redefining how medicines are made. On Tuesday, October 21 at #HLTHUSA in Las Vegas, our CEO Michael Nally will join Najat Khan, PhD of Recursion on the panel “Oh, the Places #TechBio Will Go,” moderated by Greg Yap of Menlo Ventures. They’ll explore how the convergence of AI-powered platforms and biotech expertise is transforming therapeutic development — merging computational power with biological insight to design, predict, and advance better medicines with unprecedented speed and precision.     This conversation is about shaping an era where the boundaries of medicine are continuously redrawn. Learn more: https://lnkd.in/eqkAywfv    #ProgrammingBiology | #NowWeCan

We’re excited to share that Francesco Borriello, MD, PhD, has been named to BioSpace’s inaugural “40 Under 40” — a list honoring professionals who are shaping the future by driving innovation, delivering real impact, and staying focused on improving outcomes for patients. Francesco was selected for his work translating #AI-engineered therapeutics into the clinic. That includes GB‑0895, an ultra-high affinity anti-TSLP monoclonal antibody for severe asthma that has recently completed Phase 1 and is progressing toward later-stage trials, and GB‑0669, the first AI-generated viral neutralizing antibody targeting SARS-CoV‑2, which also completed Phase 1 and demonstrated cross-variant neutralization. His leadership across these distinct programs reflects his ability to bridge computational design with clinical development. Read more about how Francesco is turning #AI-powered innovation into therapeutic progress: https://lnkd.in/eB_Xe-eS #ProgrammingBiology | #PatientsCantWait 

Science isn’t the only way we build a better future. On Saturday, we joined the Somerville Homeless Coalition’s “30th Annual 5K Road Race” — coming together with neighbors, advocates, and community partners to support housing stability for those in need. We believe progress is collective. The same spirit that drives us to push the boundaries of drug discovery and development, drives us to strengthen the community we call home. Thank you to everyone who raced, volunteered, and cheered. If this culture inspires you, join us: https://lnkd.in/gKaKkEGJ #ThisIsGenerate | #Community  

On October 8 during "2025 Fierce Biotech Week", we will share how we’re helping shape the future of communications and partnerships across the evolving biotech landscape.    ▪️"Evolving Strategic Voice: How Communicators Drive Impact in the C-Suite"   Our Chief Corporate Affairs Officer, Kym White, will join Sara Jane Baker of dna Communications, Dawn Kalmar of Stoke Therapeutics, and Monique da Silva of AnaptysBio on a panel moderated by Kelly Schlemm of Servier Pharmaceuticals to explore how strategic storytelling and transparent science communication fosters trust, drives impact, and guides organizations in an AI-driven era.     ▪️"Rethinking Platform Biotech: How Emerging Innovators Are Structuring the Future of Pharma Collaboration"   Our SVP of Business Development & Strategy, Sahm Nasseri, will join Raven Lin of Pilatus Biosciences, Mohan Uttarwar of 1Cell.Ai Inc..AI, Sam Windsor of Ignota Labs, and Hanadie Yousef of Juvena Therapeutics to share lessons from the dealmaking front lines. Together they’ll unpack how they frame value, navigate governance, and build strategic partnerships.     See how leadership is shaping the future of biotech at #FierceBiotechWeek: https://lnkd.in/guwi2eXZ    #LeadWhatsNext | #ProgrammingBiology